Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
暂无分享,去创建一个
[1] R. López-Vélez,et al. Old and new challenges in Chagas disease. , 2015, The Lancet. Infectious diseases.
[2] J. Mateus,et al. Inhibitory Receptor Expression on CD8+ T Cells Is Linked to Functional Responses against Trypanosoma cruzi Antigens in Chronic Chagasic Patients , 2015, The Journal of Immunology.
[3] S. Yusuf,et al. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. , 2015, The New England journal of medicine.
[4] L. M. Magalhães,et al. Immunoregulatory networks in human Chagas disease , 2014, Parasite immunology.
[5] I. Molina,et al. Trypanosoma cruzi infection in a non-endemic country: epidemiological and clinical profile. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[6] S. Epiphanio,et al. Chagas Disease: Still Many Unsolved Issues , 2014, Mediators of inflammation.
[7] Fernando Salvador,et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. , 2014, The New England journal of medicine.
[8] J. Ramsey,et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review , 2014, Expert review of anti-infective therapy.
[9] C. Morillo,et al. Cytokine Profiling in Chagas Disease: Towards Understanding the Association with Infecting Trypanosoma cruzi Discrete Typing Units (A BENEFIT TRIAL Sub-Study) , 2014, PloS one.
[10] R. Tarleton,et al. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. , 2013, The Journal of antimicrobial chemotherapy.
[11] M. Teixeira,et al. Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease , 2012, Seminars in Immunopathology.
[12] A. Teixeira-Carvalho,et al. Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens , 2012, BMC Infectious Diseases.
[13] R. López-Vélez,et al. EuroTravNet: imported Chagas disease in nine European countries, 2008 to 2009. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[14] P. Chiodini,et al. Chagas disease in European countries: the challenge of a surveillance system. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[15] R. López-Vélez,et al. Chagas disease in Latin American migrants: a Spanish challenge. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[16] J. Sztajzel,et al. Prevalence, Clinical Staging and Risk for Blood-Borne Transmission of Chagas Disease among Latin American Migrants in Geneva, Switzerland , 2010, PLoS neglected tropical diseases.
[17] R. López-Vélez,et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. , 2009, The Journal of antimicrobial chemotherapy.
[18] R. Tarleton,et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] S. Montgomery,et al. An estimate of the burden of Chagas disease in the United States. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] A. Teixeira-Carvalho,et al. Strategy to Assess the Overall Cytokine Profile of Circulating Leukocytes and its Association with Distinct Clinical Forms of Human Chagas Disease , 2008, Scandinavian journal of immunology.
[21] A. Teixeira-Carvalho,et al. Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. , 2008, Microbes and infection.
[22] Robert H Gilman,et al. Evaluation and treatment of chagas disease in the United States: a systematic review. , 2007, JAMA.
[23] Rodolfo Viotti,et al. Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment , 2006, Annals of Internal Medicine.
[24] J. Silver,et al. Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis. , 2001, European journal of medical research.
[25] E. Segura,et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.
[26] Simonne Almeida e Silva,et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection , 1996, The Lancet.